202 related articles for article (PubMed ID: 20037679)
1. Tiotropium HandiHaler in the treatment of COPD: a safety review.
Kesten S; Celli B; Decramer M; Leimer I; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2009; 4():397-409. PubMed ID: 20037679
[TBL] [Abstract][Full Text] [Related]
2. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
[TBL] [Abstract][Full Text] [Related]
3. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.
Casaburi R; Mahler DA; Jones PW; Wanner A; San PG; ZuWallack RL; Menjoge SS; Serby CW; Witek T
Eur Respir J; 2002 Feb; 19(2):217-24. PubMed ID: 11866001
[TBL] [Abstract][Full Text] [Related]
4. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
[TBL] [Abstract][Full Text] [Related]
5. Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan.
Hsu JY; Perng RP; Lu JY; Wu CP; Huang MS; Luh KT; Yang PC
J Formos Med Assoc; 2006 Sep; 105(9):708-14. PubMed ID: 16959618
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety of tiotropium in patients with COPD.
Celli B; Decramer M; Leimer I; Vogel U; Kesten S; Tashkin DP
Chest; 2010 Jan; 137(1):20-30. PubMed ID: 19592475
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials.
Cooper CB; Anzueto A; Decramer M; Celli B; Tashkin DP; Leimer I; Kesten S
Int J Chron Obstruct Pulmon Dis; 2011; 6():269-75. PubMed ID: 21845038
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
9. [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].
Ma J; Zhou Z; Tang Y; Zhong N
Zhonghua Nei Ke Za Zhi; 2014 Dec; 53(12):964-8. PubMed ID: 25623564
[TBL] [Abstract][Full Text] [Related]
10. Tiotropium Respimat inhaler and the risk of death in COPD.
Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
[TBL] [Abstract][Full Text] [Related]
11. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD.
Hodder R; Pavia D; Lee A; Bateman E
Int J Chron Obstruct Pulmon Dis; 2011; 6():245-51. PubMed ID: 21814460
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.
ZuWallack AR; ZuWallack RL
Expert Opin Pharmacother; 2004 Aug; 5(8):1827-35. PubMed ID: 15264997
[TBL] [Abstract][Full Text] [Related]
13. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence.
Salpeter SR
Drugs; 2009 Oct; 69(15):2025-33. PubMed ID: 19791824
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.
Wise R; Calverley PM; Dahl R; Dusser D; Metzdorf N; Müller A; Fowler A; Anzueto A
NPJ Prim Care Respir Med; 2015 Nov; 25():15067. PubMed ID: 26540491
[TBL] [Abstract][Full Text] [Related]
15. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Niewoehner DE; Rice K; Cote C; Paulson D; Cooper JA; Korducki L; Cassino C; Kesten S
Ann Intern Med; 2005 Sep; 143(5):317-26. PubMed ID: 16144890
[TBL] [Abstract][Full Text] [Related]
16. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group.
van Noord JA; Bantje TA; Eland ME; Korducki L; Cornelissen PJ
Thorax; 2000 Apr; 55(4):289-94. PubMed ID: 10722768
[TBL] [Abstract][Full Text] [Related]
18. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group.
Casaburi R; Briggs DD; Donohue JF; Serby CW; Menjoge SS; Witek TJ
Chest; 2000 Nov; 118(5):1294-302. PubMed ID: 11083677
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Tang Y; Massey D; Zhong NS
Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
[TBL] [Abstract][Full Text] [Related]
20. [Experimental inhalation therapy with nebulized tiotropium in COPD patients unable to use the Handihaler].
Yoshizawa T; Iwashiro M; Yoshizawa A
Nihon Kokyuki Gakkai Zasshi; 2010 Sep; 48(9):649-53. PubMed ID: 20954365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
